Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Endocrinology
•
Bone and Calcium Disorders
•
Primary Care
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
Answer from: at Academic Institution
My practice has been that after 2-3 years of denosumab, I wait 6 months and then start zoledronic acid.
Comments
at Endocrine Neoplasia And Hormone Deficiency Research
will uptake of ZA into bone be impaired if turnove...
17537
Sign In
or
Register
to read more
Answer from: at Community Practice
Six months after the last injection.
Sign In
or
Register
to read more
Answer from: at Community Practice
Yes, 6 months after last Prolia shot. I give 2 doses of Zoledronic 1 year apart and then consider drug holiday based on the DEXA report.
Sign In
or
Register
to read more
24261
24290
25967
Related Questions
How do you approach management of osteoporosis in patients post lung transplant?
Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?
Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
Would you recommend waiting for a low Vitamin D level to correct to goal prior to giving a scheduled Prolia injection when transitioning a patient from Zolendronic acid to Prolia therapy for worsening osteoporosis?
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy? If you workup all patients, what labs do you find most helpful to start with?
How frequently do you monitor for hypocalcemia in patients on romosozumab?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
Would you stop romosozumab if a patient developed mild asymptomatic hypocalcemia while on treatment?
will uptake of ZA into bone be impaired if turnove...